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Abstract
Background
Phosphate imbalances or disorders have a high risk of morbidity and mortality in patients
with chronic kidney disease. It is unknown if this finding extends to mortality in patients pre-
senting at an emergency room with or without normal kidney function.
Methods and Patients
This cross sectional analysis included all emergency room patients between 2010 and
2011 at the Inselspital Bern, Switzerland. A multivariable cox regression model was applied
to assess the association between phosphate levels and in-hospital mortality up to 28 days.
Results
22,239 subjects were screened for the study. Plasma phosphate concentrations were mea-
sured in 2,390 patients on hospital admission and were included in the analysis. 3.5% of the
480 patients with hypophosphatemia and 10.7% of the 215 patients with hyperphosphate-
mia died. In univariate analysis, phosphate levels were associated with mortality, age,
diuretic therapy and kidney function (all p<0.001). In a multivariate Cox regression model,
hyperphosphatemia (OR 3.29, p<0.001) was a strong independent risk factor for mortality.
Hypophosphatemia was not associated with mortality (p>0.05).
Conclusion
Hyperphosphatemia is associated with 28-day in-hospital mortality in an unselected cohort
of patients presenting in an emergency room.
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Introduction
Electrolyte disorders frequently develop in critically ill patients. In patients with chronic kidney
disease (CKD), there is derangement of phosphate homeostasis. As CKD progresses, phosphate
excretion by the kidney diminishes, which raises the serum phosphate level. This positive phos-
phate balance is further exacerbated by the impairment of the reservoir function of the skeleton
in advanced CKD [1]. Observational studies in end-stage kidney disease show a graded rela-
tionship between serum phosphate level and cardiovascular events [2,3]. Similar observations
have been made in patients with advanced CKD who are not on dialysis [4,5]. Even in people
with normal kidney function, a relative increase in serum phosphate within the normal range
has been linked to cardiovascular disease in a number of observational cohorts, prompting
some to suggest that phosphate may be the “the new cholesterol” [6–8].
In the general hospital population, the prevalence of moderate hypophosphatemia ranges
between 2.2 and 3.1% [9,10], and the prevalence of severe hypophosphatemia is reported to be
0.2 to 0.4% [11,12]. One study reports that 45% of all hospital hypophosphatemia cases occur
in an ICU population [13]. Hypophosphatemia has a higher incidence in certain patient
groups, such as patients with diabetic ketoacidosis, sepsis, and postoperative patients. Hypo-
phosphatemia is found in as many as 34% of patients after elective cardiac surgery [14]. An
extremely high incidence of hypophosphatemia is reported after major hepatic surgery, where
almost all patients develop hypophosphatemia in the first postoperative week [15,16].
In this retrospective study, we have tested whether imbalances in systemic phosphate con-
centrations are associated with in-hospital mortality in unselected patients presenting at an ER.
Materials, Methods and Patients
All patients admitted to the ER of the Inselspital, University Hospital Bern, between 1 January
2009 and 31 December 2010 were included in this cross-sectional analysis. During the study
period, 22,239 patients were enrolled in the study. In the case of multiple admissions, only the
first admission to the ER was considered for the analysis.
For these 22,239 patients, data on age, sex, admission type (medical or surgical), pre-existing
diuretic medication, country of residence, hospital admission, length of hospital stay, outcome
and final diagnosis—as classified by the International Classification of Diseases, 10th revision
(ICD-10)—were collated.
Patients who had at least one cardiovascular, neurological or metabolic, nephrologic, intesti-
nal or hepatic comorbidity alongside the primary reason for admission received a blood test
including Phosphate concentration.
Plasma phosphate concentrations0.75 mmol/l were considered as hypophosphatemia,
concentrations between 0.75 and 1.45 as normal/physiological levels and1.46 mmol/l as
hyperphosphatemia.
A waiver for informed consent was provided for this retrospective analysis of pseudonony-
mized data. Data were analyzed anonymously. Due to ethical and legal restrictions in accor-
dance with the guidelines provided by the ethical committee of Bern data are available upon
request from the authors who may be contacted at the corresponding author address, the
Department of Emergency Medicine at the University Hospital of Bern. The study protocol
was approved by the Ethics Committee of the Canton of Bern, Switzerland.
Statistical Analysis
Data are presented as medians (IQR) or proportions, as appropriate. Between-group compari-
sons of continuous variables were performed using the Mann–Whitney U test.
Pearson’s Chi-Square Test was used for the identification of associations with survival.
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Cox regression analysis was used to explore the association of the various predictors with
the presence of electrolyte disorders and with hospitalization. Predefined covariates were
added to the logistic regression models. Cox regression was used to test associations of the
diuretics with the survival time adjusted for predefined covariates.
A two-sided P value of<0.05 was considered statistically significant for all analyses. The sta-
tistical analysis was performed using SPSS (SPSS for Windows V.17.0, Chicago, IL, USA).
Results
22,239 patients admitted to the ER during the observation period were screened for alterations
in systemic phosphate levels (Fig 1). 19,849 patients were excluded because no phosphate con-
centrations were available from laboratory reports on hospital entry and 2,390 patients were
included in the analysis (Fig 1). Patients had a median age of 57 (range 40 to 71) years and
Fig 1. Patient flow chart.
doi:10.1371/journal.pone.0133426.g001
Table 1. Baseline characteristics of patients on hospital admission (n = 2390). Medians with IQRs.
Parameter Median (IQR)
Length of hospital stay (days) 3 (0;9)
Age (years) 57 (40;71)
eGFR (MDRD) (ml/min/1,73m2) 89.4 (57.4;114.4)
Sodium (mmol/l) 139 (136;141)
Chloride (mmol/l) 103 (99;106)
Phosphate (mmol/l) 1.9 (0.8;1.2)
Calcium (mmol/l) 2.25 (2.15;2.34)
Potassium (mmol/l) 3.9 (3.7;4.3)
Magnesium (mmol/l) 0.8 (0.72;0.88)
Osmolality (mosm/kg) 291 (283;306)
doi:10.1371/journal.pone.0133426.t001
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1399 (58.5%) were male. Baseline characteristics are shown in Table 1 and Table 2. Median
length of hospital stay was 3 (range 0 to 9) days and 28-day in-hospital mortality was 3.2%
(n = 77).
When compared with patients with physiological phosphate levels, patients with hyperpho-
sphatemia were 8 years older (57 vs. 65 years, p<0.05), stayed 3 more days in hospital, had
lower eGFR, sodium, chloride and calcium but higher potassium, magnesium and osmolality
(Table 3). On average, patients with hypophosphatemia were 3 years younger than patients
with physiological phosphate levels (54 years, p<0.05) and their systemic magnesium, potas-
sium and osmolality also differed (Table 3).
In univariate analysis, phosphate levels were strongly associated with mortality and eGFR
(Table 4). In a multivariate Cox regression model, only hyperphosphatemia was an indepen-
dent risk factor for mortality (Table 5). In contrast, hypophosphatemia was not associated with
mortality in multivariate Cox regression (Table 6). In this group of patients, only eGFR was an
independent risk factor for mortality (Table 6). For ethnicity no statistical result could be
obtained as too few cases were included (Tables 5 and 6).
The Kaplan Meier curve shows that the increase in mortality in patients with hyperpho-
sphatemia becomes apparent between days 2 and 5 after hospital admission (Fig 2).
Discussion
Our study demonstrates that hyperphosphatemia is an independent predictor for mortality in
patients presenting at an ER. In patients with hypophosphatemia, only eGFR remains indepen-
dently associated with mortality.
Hyperphosphatemia has been repeatedly linked to CKD [1–8].While hyperphosphat-emia
may be a tangible indicator of deteriorating kidney function, it appears that lack of phosphate
Table 2. Baseline characteristics of patients on hospital admission (n = 2390).
Parameter Total number (n =)
Ethnicity (African/Caucasian) 27/2363
Mortality 77
Patients with diuretic therapy 510
Sex (m/f) 1399/991
doi:10.1371/journal.pone.0133426.t002
Table 3. Data is presented as mean values with IQRs.
Hypophosphatemia Normophosphatemia Hyperphosphatemia
Length of hospital stay (days) 3 (0;8) 3 (0;3) 6 (1;14)*
eGFR(MDRD) (ml/min/1,73m2) 90.7 (65.5;114.3) 92.8 (64.0;92.7) 22.4 (11.7;64.6)*
Sodium (mmol/l) 139 (135;141) 139 (136;139) 137 (133;140)*
Chloride (mmol/l) 104 (100:106) 103 (100;103) 101 (96;106)*
Phosphate (mmol/l) 0.68 (0.57;0.75)* 1.04 (0.93;1.04) 1.83 (1.63;2.23)*
Calcium (mmol/l) 2.24 (2.13;2.34) 2.26 (2.17;2.26) 2.17 (2.05;2.23)*
Potassium (mmol/l) 3.8 (3.5;4.1)* 4.0 (3.7;4.0) 4.4 (3.9;5.2)*
Magnesium (mmol/l) 0.77 (0.68;0.83)* 0.81 (0.73;0.81) 0.93 (0.81;1.04)*
Osmolality (mosm/kg) 288 (282;293)* 291 (283;291) 311 (295;328)*
Statistical testing shows group comparison of patients with hypophosphatemia (n = 480) and hyperphosphatemia (n = 215) versus patients with serum
phosphate within the normal range (n = 1695) (Mann-Whitney U, p<0.05*).
doi:10.1371/journal.pone.0133426.t003
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homeostasis may also be associated with the increased risk of cardiovascular events and mor-
tality that has become a hallmark of CKD [2–6]. The need to maintain phosphorus concentra-
tions within a recommended range is reflected in evidence-based guidelines. However, no
studies have been performed to investigate the influence of phosphate levels on the outcomes
of patients presenting at an ER. Although we detected strong associations with kidney function,
hyperphosphatemia remained an independent risk factor for mortality in the multivariate anal-
yses. There is evidence that phosphate additives in food may harm the health of persons with
normal renal function [17]. More recent studies have shown that the association between high
phosphate concentrations and higher mortality is not restricted to persons with renal disease; it
can also be observed in persons with cardiovascular disease and even in the general population.
High-normal serum phosphate concentrations are associated with coronary calcification in
Table 5. Multivariate Cox regression analysis for mortality in patients with hyperphosphatemia (A)
and patients with hypophosphatemia (B).
Parameter OR (95% CI) p-value
Hyperphosphatemia 3.29 (1.8;6.1) <0.001*
Sex 0.29 (0.8;2.3) 0.34
Age 1.01 (0.9;1.0) 0.07
Diuretic therapy 0.7 (0.4;1.3) 0.22
eGFR 1.0 (0.9;1.0) 0.83
Ethnicity n.a. n.a.
(p<0.05*), data presented in odds ratios (OR) with 95% conﬁdence intervals (95% CI).
doi:10.1371/journal.pone.0133426.t005
Table 4. Associations of phosphate levels with different parameters in univariate analysis.
Parameter p-value
Sex 0.054
Mortality <0.001*
Ethnicity 0.91
Diuretic therapy <0.001*
Age <0.01*
eGFR <0.001*
Pearson’s Chi-Square Test (p<0.05*).
doi:10.1371/journal.pone.0133426.t004
Table 6. Multivariate Cox regression analysis for mortality in patients with with hypophosphatemia.
Parameter OR (95% CI) p-value
Hypophosphatemia 1.24 (0.66;2.30) 0.51
Sex 1.28 (0.75;1.28) 0.36
Age 1.01 (0.99;1.03) 0.10
Diuretic therapy 0.75 (0.42;1.35) 0.33
eGFR 1.001 (1.00;1.002) 0.008*
Ethnicity n.a. n.a.
(p<0.05*), data presented in odds ratios (OR) with 95% conﬁdence intervals (95% CI).
doi:10.1371/journal.pone.0133426.t006
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young, healthy men and were found to be a predictor of cardiovascular events in the Framing-
ham study [18,19]. Elevated mortality in association with high-normal serum phosphate con-
centrations was seen mainly among persons with cardiovascular disease who had normal renal
function [20]. Our results strengthen these findings and emphasize that hyperphosphatemia is
an electrolyte disorder that should be controlled in patients presenting at an ER.
In the present study, we found no association between hypophosphatemia and mortality.
On the other hand, many other studies have found an association between hypophosphatemia
and increased mortality [13,14,21–28]. Severe hypophosphatemia has been reported to predict
an increase of up to 8-fold in mortality in sepsis patients [21]. However, hypophosphatemia
has not been associated with increased mortality after cardiac surgery and in diabetic ketoaci-
dosis [14,23]. Overall, it therefore remains unclear whether hypophosphatemia actually con-
tributes to mortality, or is merely a marker for severe illness.
In summary, hyperphosphatemia is an independent predictor for mortality in an unselected
patients cohort presenting at an ER. Hypophosphatemia was not associated with mortality in
these patients.
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Fig 2. Kaplan-Meier curve for 28 day in-hospital mortality in patients with hyperphosphatemia (grey
line) versus patients with hypophosphatemia (blue line) and patients with normal phosphate levels
(green line) (p<0.001).
doi:10.1371/journal.pone.0133426.g002
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